Sana Biotechnology, Inc.

NASDAQ:SANA

Biotechnology

Healthcare
$1.85 +1.23%

+$0.04 today

Market cap
$554.32M
Beta
2.16
P/E (TTM)
-3.5
EPS (TTM)
-$0.87
52W Low $2.58High $6.55

Volume 2.66M

Average 3.76M

SANA Total Debt

Short-term and long-term borrowings combined.

Sana Biotechnology, Inc.NASDAQ: SANA

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 17.5% from a year ago

Total debt stood at $75.33M at the end of Q1 FY2026, down 17.5% from a year earlier and down 4.5% from the prior quarter. Over 3 fiscal years it compounded at -10.0% a year.

Context

  • Total debt amounted to 20.2% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
  • Total debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -17.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$75.33M-4.5% QoQ
Last fiscal yearDec 2025
$78.86M-16.3% YoY
Year agoMar 2025
$91.31M-17.5% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.5%——
1 year-16.3%——
3-year CAGR-10.0%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
78.86M USD
Year-over-year change
-16.3%
4-year CAGR
-8.2%

Total Debt vs competitors

How SANA compares with its peers on the latest reported figures

  • SANA's Mar 2026 total debt of $75.33M is the 7th highest of the 11 companies compared; the peer median is $78.64M.
  • Its year-over-year change of -17.5% is the 8th highest of 11, against a peer median of -6.1%.
  • Total debt amounts to 20.2% of total assets for SANA, versus a peer median of 18.8%.
SANA Competitors Peer median
Total Debt for SANA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CRSPCRISPR Therapeutics AGSep 2026$779.83M +93.1%+17.4%30.5%
BEAMBeam Therapeutics Inc.Jun 2026$247.36M +59.8%+18.0%17.8%
LEGNLegend Biotech CorporationSep 2026$167.4M -59.2%+13.3%10.0%
ALLOAllogene Therapeutics, Inc.Mar 2026$81.05M -0.3%-6.3%20.5%
NTLAIntellia Therapeutics, Inc.Mar 2026$80.49M -32.5%-10.6%10.6%
FATEFate Therapeutics, Inc.Mar 2026$76.79M -7.9%-10.7%27.0%
SANASana Biotechnology, Inc.Mar 2026$75.33M -17.5%-10.0%20.2%
IPSCCentury Therapeutics, Inc.Mar 2026$48.03M -8.8%-4.1%14.7%
DTILPrecision BioSciences, Inc.Mar 2026$28.47M -4.3%+4.9%19.8%
ATRAAtara Biotherapeutics, Inc.Mar 2026$10.09M -81.7%-9.7%50.5%
CGEMCullinan Therapeutics, Inc.Mar 2026$2.38M +29.5%-19.7%0.6%
Peer median (excluding SANA) $78.64M-6.1%-5.2%18.8%

Competitors are the stored peer set for SANA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents253.03M176.77M133.52M127.57M71.87M
Short-term Investments297.97M247.2M71.68M24.93M66.51M
Net Receivables00000
Inventory00000
Other Current Assets020.47M8.32M8.31M10.29M
Total Current Assets558.1M444.44M213.52M160.81M148.68M
Property, Plant & Equipment (Net)161.78M159.4M145.59M135.27M65.22M
Goodwill140.63M140.63M140.63M140.63M140.63M
Intangible Assets59.2M59.2M59.2M59.2M59.2M
Long-term Investments195.88M10.05M000
Tax Assets00000
Other Non-current Assets13.82M9.01M6.37M5.12M3.17M
Total Non-current Assets571.31M378.28M351.78M340.21M268.21M
Total Assets1.13B822.72M565.3M501.02M416.89M
Account Payables2.22M2.86M4.11M5.21M1.67M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities74.63M76.59M23.46M300K51.93M
Total Current Liabilities99.24M111.5M64.49M45.43M78.73M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities199.89M116.04M122.41M123.42M113.36M
Total Non-current Liabilities301.67M211.9M213.31M205.08M177.28M
Total Liabilities400.91M323.41M277.79M250.52M256.01M
Common Stock18K19K20K22K27K
Retained Earnings(785.36M)(1.05B)(1.34B)(1.6B)(1.85B)
Accumulated OCI(1.37M)(4.33M)(60K)14K28K
Other Stockholders Equity00000
Minority Interest00000
Total Equity728.5M499.32M287.51M250.5M160.88M
Total Debt110.94M108.25M104.1M94.2M78.86M
Net Debt(142.09M)(68.51M)(29.42M)(33.37M)6.99M

Sana Biotechnology, Inc.

NASDAQ:SANA

Intrinsic Alpha fair value

Locked

Current Price

$1.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.